The relevance of factor VIII inactivation characteristics in the treatment of patients with antibodies directed against factor VIII.
D000818:Animals; D000906:Antibodies; D000937:Antigen-Antibody Reactions; D005169:Factor VIII; D006467:Hemophilia A / Q000150:complications / Q000276:immunology* / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D013552:Swine; D013978:Tibial Fractures / Q000150:complications; D013997:Time Factors
D000906:Antibodies; D005169:Factor VIII; D011239:Prednisolone